drugset / Trial / NCT04107194

Non-invasive Test-guided Tailored Therapy Versus Empiric Treatment for Helicobacter Pylori Infection.

NCT04107194 ↗

Phase 3 Unknown 362 enrolled University of Bari
RandomizedParallel-groupSingle-blindTreatment

Summary

The aim of our study will be to assess in an open-label, multicenter, randomized controlled trial whether a tailored therapy guided by a non-invasive antibiotic susceptibility test on stool samples achieves higher Helicobacter eradication rates than an empiric antibiotic regimen. For this purpose, consecutive patients with dyspeptic symptoms, diagnosis of Helicobacter pylori infection and naïve to eradicating treatments will be allocated to either of the two intervention arms.

Timeline

Start
2020-01-14
Primary completion
2021-02-14
Completion
2022-04-14

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Amoxicillin Other / unclassified 1000 mg —
Subject Bismuth subcitrate Unknown 140 mg —
Subject Clarithromycin Small molecule 500 mg —
Subject Levofloxacin Small molecule 500 mg —
Subject Metronidazole Small molecule 125 mg —
Subject Metronidazole Small molecule 500 mg —
Subject Rifabutin Small molecule 150 mg —
Subject Tetracycline Unknown 125 mg —
Background Pantoprazole Other / unclassified 40 mg —